Telix Hit With Securities Class Action Over Prostate-Drug Claims and Supply Chain Assurances

Overview

• The complaint, captioned Thomas v. Telix Pharmaceuticals Ltd., was filed in the U.S. District Court for the Southern District of Indiana.
• The proposed class covers investors who bought Telix securities from February 21, 2025 through August 28, 2025.
• Filings allege Telix overstated the development and commercial prospects of prostate cancer candidates TLX591 and TLX592.
• The suit also alleges Telix overstated the reliability and regulatory compliance of third‑party manufacturing partners, citing FDA Form 483 observations tied to TLX250‑CDx (Zircaix).
• Notices highlight a drop of more than 13% in ADSs after Telix disclosed an SEC subpoena on July 22, 2025 and a further decline of over 21% after an FDA complete response letter on August 28, 2025, with a lead‑plaintiff deadline of January 9, 2026 and multiple firms soliciting investors.